<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>
<channel>
	<title>Orthopedic Product Guide &#187; biocomposite</title>
	<atom:link href="http://blog.orthopedicproductguide.com/category/biocomposite/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.orthopedicproductguide.com</link>
	<description>A comprehensive guide to orthopedic products for medical professionals </description>
	<lastBuildDate>Wed, 29 Sep 2010 14:31:20 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.3</generator>
		<item>
		<title>FDA Accepts PMA Application for Augment Bone Graft</title>
		<link>http://blog.orthopedicproductguide.com/2010/07/07/fda-accepts-pma-application-for-augment-bone-graft/</link>
		<comments>http://blog.orthopedicproductguide.com/2010/07/07/fda-accepts-pma-application-for-augment-bone-graft/#comments</comments>
		<pubDate>Wed, 07 Jul 2010 18:26:41 +0000</pubDate>
		<dc:creator>Josie Rich</dc:creator>
				<category><![CDATA[biocomposite]]></category>
		<category><![CDATA[bone loss]]></category>
		<category><![CDATA[FDA Application]]></category>
		<category><![CDATA[Foot and Ankle]]></category>
		<category><![CDATA[Augment Bone Graft]]></category>
		<category><![CDATA[BioMimetic Therapeutics]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[PMA]]></category>
		<category><![CDATA[Premarket Approval]]></category>
		<guid isPermaLink="false">http://www.orthopedicproductguide.com/blog/?p=291</guid>
		<description><![CDATA[BioMimetic Therapeutics Inc announced that the US Food &#38; Drug Administration (FDA) has accepted for review its Premarket Approval (PMA) application for Augment Bone Graft for use in foot and ankle fusions in the US. The FDA has now filed the application and begun the comprehensive review of the clinical module, the company added. FDA [...]]]></description>
			<content:encoded><![CDATA[<p>BioMimetic Therapeutics Inc announced that the US Food &amp; Drug Administration (FDA) has accepted for review its Premarket Approval (PMA) application for Augment Bone Graft for use in foot and ankle fusions in the US. The FDA has now filed the application and begun the comprehensive review of the clinical module, the company added.</p>
<div style="overflow: hidden;width: 1px;height: 1px"><!--[if gte mso 9]&gt;  Normal 0   false false false        MicrosoftInternetExplorer4  &lt;![endif]--><!--[if gte mso 9]&gt;   &lt;![endif]--><!--[if !mso]&gt;<span class="mceItemObject"></span> &lt;!  st1\:*{behavior:url(#ieooui) } &#8211;> <!--[endif]--><!--  /* Style Definitions */  p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-parent:""; 	margin:0in; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} @page Section1 	{size:8.5in 11.0in; 	margin:1.0in 1.25in 1.0in 1.25in; 	mso-header-margin:.5in; 	mso-footer-margin:.5in; 	mso-paper-source:0;} div.Section1 	{page:Section1;} --><!--[if gte mso 10]&gt; &lt;!   /* Style Definitions */  table.MsoNormalTable 	{mso-style-name:&quot;Table Normal&quot;; 	mso-tstyle-rowband-size:0; 	mso-tstyle-colband-size:0; 	mso-style-noshow:yes; 	mso-style-parent:&quot;&quot;; 	mso-padding-alt:0in 5.4pt 0in 5.4pt; 	mso-para-margin:0in; 	mso-para-margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:10.0pt; 	font-family:&quot;Times New Roman&quot;; 	mso-ansi-language:#0400; 	mso-fareast-language:#0400; 	mso-bidi-language:#0400;} --> <!--[endif]--></p>
<p class="MsoNormal">FDA Accepts PMA Application for Augment Bone Graft</p>
<p class="MsoNormal">BioMimetic Therapeutics, Inc announced that the US Food &amp; Drug Administration (FDA) has accepted for review its Premarket Approval (PMA) application for Augment Bone Graft for use in foot and ankle fusions in the US. The FDA has now filed the application and begun the comprehensive review of the clinical module, the company added.</p>
</div>
]]></content:encoded>
			<wfw:commentRss>http://blog.orthopedicproductguide.com/2010/07/07/fda-accepts-pma-application-for-augment-bone-graft/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biocomposites Launches GeneX(R)ds. Extending The Reach Of Injectable Bone Grafts</title>
		<link>http://blog.orthopedicproductguide.com/2010/01/14/repeat-biocomposites-launches-genexrds-extending-the-reach-of-injectable-bone-grafts/</link>
		<comments>http://blog.orthopedicproductguide.com/2010/01/14/repeat-biocomposites-launches-genexrds-extending-the-reach-of-injectable-bone-grafts/#comments</comments>
		<pubDate>Thu, 14 Jan 2010 07:46:13 +0000</pubDate>
		<dc:creator>Josie Rich</dc:creator>
				<category><![CDATA[biocomposite]]></category>
		<category><![CDATA[Biocomposites]]></category>
		<category><![CDATA[geneX ds]]></category>
		<category><![CDATA[resorbable bone graft]]></category>
		<guid isPermaLink="false">http://www.orthopedicproductguide.com/blog/?p=190</guid>
		<description><![CDATA[Biocomposites has launched geneX ds, a dual syringe mixing and minimally invasive delivery system containing geneX, the unique resorbable bone graft material with a negative surface charge. The powder and liquid components of geneX are provided pre-packed in separate syringes. The syringes connect together and allow a faster, simpler and cleaner way for mixing geneX. [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://blog.orthopedicproductguide.com/files/2010/01/biocomposites.png"><img class="alignleft size-full wp-image-191" style="margin: 5px" src="http://blog.orthopedicproductguide.com/files/2010/01/biocomposites.png" border="0" alt="biocomposites" width="200" height="53" /></a>Biocomposites has launched geneX ds, a dual syringe mixing and minimally invasive delivery system containing geneX, the unique resorbable bone graft material with a negative surface charge. The powder and liquid components of geneX are provided pre-packed in separate syringes. The syringes connect together and allow a faster, simpler and cleaner way for mixing geneX. The resulting setting paste can then be delivered through a 3.15&#8243; dispenser (included).</p>
<p>For the full story, <a href="http://www.medicalnewstoday.com/articles/175726.php" target="_blank">Click Here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://blog.orthopedicproductguide.com/2010/01/14/repeat-biocomposites-launches-genexrds-extending-the-reach-of-injectable-bone-grafts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Depuy Mitek Launches Healix™ Br With Biocryl(R) Rapide™, Leading U.S. Biocomposite Material For Shoulder, Knee Implants</title>
		<link>http://blog.orthopedicproductguide.com/2008/12/02/depuy-mitek-launches-healix%e2%84%a2-br-with-biocrylr-rapide%e2%84%a2-leading-us-biocomposite-material-for-shoulder-knee-implants/</link>
		<comments>http://blog.orthopedicproductguide.com/2008/12/02/depuy-mitek-launches-healix%e2%84%a2-br-with-biocrylr-rapide%e2%84%a2-leading-us-biocomposite-material-for-shoulder-knee-implants/#comments</comments>
		<pubDate>Tue, 02 Dec 2008 12:16:26 +0000</pubDate>
		<dc:creator>Josie Rich</dc:creator>
				<category><![CDATA[biocomposite]]></category>
		<category><![CDATA[Implants]]></category>
		<category><![CDATA[Sports Medicine]]></category>
		<category><![CDATA[biocomposite material]]></category>
		<category><![CDATA[BIOCRYL® RAPIDE™]]></category>
		<category><![CDATA[DePuy Mitek]]></category>
		<category><![CDATA[HEALIX™]]></category>
		<guid isPermaLink="false">http://www.orthopedicproductguide.com/blog/2008/12/02/depuy-mitek-launches-healix%e2%84%a2-br-with-biocrylr-rapide%e2%84%a2-leading-us-biocomposite-material-for-shoulder-knee-implants/</guid>
		<description><![CDATA[DePuy Mitek, Inc. has announced the launch of the HEALIX™ BR Dual Threaded Anchor System, the first suture anchor for arthroscopic rotator cuff repair made with the company&#8217;s proprietary BIOCRYL® RAPIDE™ biocomposite material, shown in pre-clinical trials to resorb and promote bone formation within the implant profile2. BIOCRYL RAPIDE has become an important technology platform [...]]]></description>
			<content:encoded><![CDATA[<p><img src="http://blog.orthopedicproductguide.com/files/2008/12/depuy-mitek.png" vspace="5" width="200" align="left" height="58" hspace="5" /><a href="http://www.depuymitek.com">DePuy Mitek, Inc</a>. has announced the launch of the HEALIX™ BR Dual Threaded Anchor System, the first suture anchor for arthroscopic rotator cuff repair made with the company&#8217;s proprietary BIOCRYL® RAPIDE™ biocomposite material, shown in pre-clinical trials to resorb and promote bone formation within the implant profile2. BIOCRYL RAPIDE has become an important technology platform in orthopedics sports medicine. The biocomposite material, exclusive to DePuy Mitek products, has more than four years of clinical success in more than 100,000 patients. BIOCRYL RAPIDE is currently used in the MILAGRO Bioreplaceable Interference Screw for anterior cruciate ligament (ACL) repair.</p>
]]></content:encoded>
			<wfw:commentRss>http://blog.orthopedicproductguide.com/2008/12/02/depuy-mitek-launches-healix%e2%84%a2-br-with-biocrylr-rapide%e2%84%a2-leading-us-biocomposite-material-for-shoulder-knee-implants/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Osteotech receives FDA nod for Plexur P</title>
		<link>http://blog.orthopedicproductguide.com/2008/04/30/osteotech-receives-fda-nod-for-plexur-p/</link>
		<comments>http://blog.orthopedicproductguide.com/2008/04/30/osteotech-receives-fda-nod-for-plexur-p/#comments</comments>
		<pubDate>Wed, 30 Apr 2008 14:40:36 +0000</pubDate>
		<dc:creator>Josie Rich</dc:creator>
				<category><![CDATA[biocomposite]]></category>
		<category><![CDATA[bone loss]]></category>
		<category><![CDATA[FDA approval]]></category>
		<category><![CDATA[Foot and Ankle]]></category>
		<category><![CDATA[bone void filler]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[graft extender]]></category>
		<category><![CDATA[Osteotech]]></category>
		<category><![CDATA[Plexur P]]></category>
		<category><![CDATA[spine surgeon]]></category>
		<category><![CDATA[tibial osteotomy]]></category>
		<category><![CDATA[tibial plateau fracture]]></category>
		<guid isPermaLink="false">http://www.orthopedicproductguide.com/blog/2008/04/30/osteotech-receives-fda-nod-for-plexur-p/</guid>
		<description><![CDATA[The FDA has cleared Osteotech Inc.’s Plexur P biocomposite for use in spinal applications as a bone void filler and graft extender. Osteotech has already received FDA clearance for Plexur P for use in filling bony voids of the pelvis and extremities. The biocomposite has been used in tibial plateau fractures, tibial osteotomies and foot [...]]]></description>
			<content:encoded><![CDATA[<p><img border="0" vspace="5" align="left" width="238" src="http://blog.orthopedicproductguide.com/files/2008/04/plexur-logo.png" hspace="5" alt="Plexur Logo" height="44" />The FDA has cleared Osteotech Inc.’s <a href="http://www.plexur.com">Plexur P</a> biocomposite for use in spinal applications as a bone void filler and graft extender. Osteotech has already received FDA clearance for Plexur P for use in filling bony voids of the pelvis and extremities. The biocomposite has been used in tibial plateau fractures, tibial osteotomies and foot and ankle procedures. The company aims to immediately offer our Plexur P(TM) product to spine surgeons.</p>
]]></content:encoded>
			<wfw:commentRss>http://blog.orthopedicproductguide.com/2008/04/30/osteotech-receives-fda-nod-for-plexur-p/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Osteotech gets FDA nod for Plexur M(TM) Biocomposite</title>
		<link>http://blog.orthopedicproductguide.com/2008/03/07/osteotech-gets-fda-nod-for-plexur-mtm-biocomposite/</link>
		<comments>http://blog.orthopedicproductguide.com/2008/03/07/osteotech-gets-fda-nod-for-plexur-mtm-biocomposite/#comments</comments>
		<pubDate>Fri, 07 Mar 2008 16:31:09 +0000</pubDate>
		<dc:creator>Josie Rich</dc:creator>
				<category><![CDATA[biocomposite]]></category>
		<category><![CDATA[FDA approval]]></category>
		<category><![CDATA[Spine]]></category>
		<category><![CDATA[filling]]></category>
		<category><![CDATA[Osteotech]]></category>
		<category><![CDATA[Plexur M(TM)]]></category>
		<guid isPermaLink="false">http://www.orthopedicproductguide.com/blog/2008/03/07/osteotech-gets-fda-nod-for-plexur-mtm-biocomposite/</guid>
		<description><![CDATA[Osteotech Inc. has received FDA approval for its 510(k) submission for its Plexur M(TM) Biocomposite. Plexur M is intended for use in filling bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure. During the healing process, Plexur M is remodeled and replaced by host bone. [...]]]></description>
			<content:encoded><![CDATA[<p><img border="0" vspace="5" align="right" width="283" src="http://blog.orthopedicproductguide.com/files/2008/03/plexur-biocomposite.jpg" hspace="5" alt="Plexxur Biocomposite" height="154" /><a href="http://www.osteotech.com/">Osteotech Inc</a>. has received FDA approval for its 510(k) submission for its Plexur M(TM) Biocomposite. Plexur M is intended for use in filling bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure. During the healing process, Plexur M is remodeled and replaced by host bone. When heated, Plexur M becomes moldable and pliable, which allows surgeons various options for use during surgery. During the cooling process, Plexur M hardens, providing a versatile porous scaffold to help in regeneration of damaged and diseased bones.</p>
<p>Osteotech’s president and CEO Sam Owusu-Akyaw has indicated that the company intends to file an additional submission for the use of this product in spinal applications during the second quarter of the year.</p>
]]></content:encoded>
			<wfw:commentRss>http://blog.orthopedicproductguide.com/2008/03/07/osteotech-gets-fda-nod-for-plexur-mtm-biocomposite/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

